Discover small cap exploration stocks
We are a small team of investors building a high performing ASX small cap stock portfolio and sharing our investing journey with our readers for free.
Finfeed is following on from one of Australia’s most successful biotech and life sciences fund managers to select and invest in early to mid-stage ASX listed biotechs.
| Stocks |
Date of Initial Coverage
|
Initial Entry Price
|
Last Price
|
Portfolio Weighting | Shares Held | Macro Theme | Actively Sharing | Highest Point |
Performance from Initial Entry
|
|---|---|---|---|---|---|---|---|---|---|
| EMD | 04-Sep-2023 | $0.075 | $0.072 | Biotech | 65% | -4% | |||
| ALA | 18-Feb-2022 | $0.038 | $0.094 | Biotech | 189% | 147% | |||
| DXB | 16-Aug-2021 | $0.200 | $0.140 | Biotech | 45% | -30% | |||
| NTI | 18-Sep-2023 | $0.045 | $0.057 | None | 191% | 28% |
| Stocks |
Date of Initial Coverage
|
Initial Entry Price
|
Last Price
|
Portfolio Weighting | Shares Held | Macro Theme | Actively Sharing | Highest Point |
Performance from Initial Entry
|
|---|---|---|---|---|---|---|---|---|---|
| EMD | 04-Sep-2023 | $0.075 | $0.072 | Biotech | 65% | -4% | |||
| ALA | 18-Feb-2022 | $0.038 | $0.094 | Biotech | 189% | 147% | |||
| DXB | 16-Aug-2021 | $0.200 | $0.140 | Biotech | 45% | -30% | |||
| NTI | 18-Sep-2023 | $0.045 | $0.057 | None | 191% | 28% |